Microvascular Decompression in Octogenarians: Rethinking Age Limits in Trigeminal Neuralgia Surgery

Microvascular decompression (MVD) has long been considered the gold standard surgical treatment for trigeminal neuralgia (TN). Yet patients aged 80 years and older are often excluded from this option due to concerns about surgical risk. A new Cleveland Clinic study published in Neurosurgery challenges this assumption, demonstrating that MVD can be both safe and effective in carefully selected octogenarian patients, with outcomes comparable to those seen in younger individuals.

Treating older patients

Trigeminal neuralgia is a debilitating neuropathic condition characterized by sudden, severe, paroxysmal facial pain affecting one or more branches of the trigeminal nerve. The disorder is most commonly caused by neurovascular compression at the trigeminal nerve root entry zone, and its incidence increases with age.

Microvascular decompression addresses the underlying pathology by surgically repositioning the offending blood vessel away from the nerve. Unlike ablative procedures, MVD preserves nerve function and offers the most durable pain relief. However, elderly patients – particularly those in their 80s – have historically been steered toward less invasive neuroablative treatments due to concerns about surgical morbidity.

“Microvascular decompression may actually be technically easier in octogenarians due to age-related reduction in brain volume, which can facilitate access to the trigeminal nerve,” notes Hamid Borghei-Razavi, MD, a board-certified neurosurgeon with the Headache & Facial Pain Center at Cleveland Clinic Weston Hospital and Director of Cleveland Clinic’s Brain Tumor and Pituitary Center in Florida.

Another important consideration is medication intolerance. First-line pharmacologic therapies for TN, such as carbamazepine and oxcarbazepine, frequently cause adverse effects in older patients, including hyponatremia, confusion, dizziness, and gait instability.

“Generally, it’s very hard for older patients to tolerate these medications,” explains Dr. Borghei-Razavi. “With surgery, we can eliminate these drugs and offer meaningful improvements in overall quality of life.”

Addressing a critical evidence gap

While prior studies have included patients aged 70 and older, none had specifically examined outcomes of MVD in octogenarians versus younger patients. To address this gap, Cleveland Clinic investigators from Florida and Ohio collaborated on a retrospective, propensity score-matched cohort study evaluating the safety and efficacy of MVD in patients aged 80 years and older with classic TN.

The study included cases performed between 2018 and 2024 at Cleveland Clinic’s main campus in Ohio and Cleveland Clinic Weston Hospital by three surgeons: Varun Kshettry, MD, Surgical Director of the Cleveland Clinic Trigeminal Neuralgia Program in Cleveland; Badih Adada, MD, Chair of the Neurological Institute at Cleveland Clinic in Florida and Chair of the Department of Neurosurgery; and Dr. Borghei-Razavi.

A total of 280 patients were initially identified, including 33 octogenarians and 247 patients younger than 80 years. After excluding patients with prior MVD and applying 4:1 propensity score matching, 152 matched patients were included in the primary analysis.

Baseline characteristics were largely similar between groups. Octogenarians had a lower median body mass index (25.8 kg/m² vs. 28.1 kg/m², p=0.0186) and a higher prevalence of arrhythmia (15.2% vs. 3.9%, p=0.0163). No other statistically significant differences in comorbidities were observed.

Equivalent pain relief and perioperative outcomes

Pain outcomes were assessed using preoperative and postoperative Barrow Neurological Institute (BNI) pain scores, along with perioperative metrics and complication rates. Postoperatively, octogenarian patients experienced pain relief comparable to that of younger patients, with similar improvements in BNI pain scores.

There were no significant differences between age groups in length of hospital stay, readmission rates, reoperation rates, or overall medical and surgical complications. Octogenarians did experience a higher rate of new or worsened arrhythmia (6.1% vs. 0%, p=0.0405), but this did not translate into worse overall outcomes.

“The higher rates of arrhythmia among octogenarians did not lead to increased morbidity or mortality,” says first author Mohammadmahdi Sabahi, MD, MPH, a postdoctoral research fellow in the Department of Neurosurgery at Cleveland Clinic in Florida.

The investigators concluded that octogenarian patients can achieve pain relief and postoperative outcomes comparable to those of younger patients undergoing MVD. “Age alone should not preclude patients from undergoing microvascular decompression,” adds Dr. Borghei-Razavi.

Keys to success: patient selection and enhanced recovery

Unlike earlier reports suggesting higher rates of mortality or stroke among elderly neurosurgical patients, the Cleveland Clinic cohort did not demonstrate these complications. Dr. Borghei-Razavi attributes these favorable outcomes to meticulous patient selection, refined surgical techniques, and standardized perioperative care.

Only patients in good overall health with preserved mobility were considered candidates for MVD. Early postoperative ambulation also was emphasized to reduce the risk of complications such as deep vein thrombosis and pulmonary embolism.

“Lack of mobility and serious cardiovascular disease requiring ongoing anticoagulation are contraindications for MVD in octogenarians,” confirms Dr. Borghei-Razavi. Patients with severe comorbidities were instead offered alternative neuroablative procedures when appropriate.

Expanding surgical boundaries for older patients

Cleveland Clinic surgeons have offered MVD to octogenarians for nearly a decade. This experience builds on prior institutional research showing that octogenarians undergoing craniotomy for brain tumor resection did not experience increased 30-day readmission, mortality, or postoperative complications compared with younger patients.

The researchers emphasize the need for future studies examining patient-reported outcomes, satisfaction, and long-term efficacy of MVD in octogenarians. While most younger patients remain pain free five years after surgery, similar long-term data are needed in older populations.

“Before, it was a taboo to touch anyone over 80,” Dr. Borghei-Razavi says. “But our outcomes show that, with proper selection, we can safely perform this surgery and give these patients their lives back.”